Markets:

Overview

News

Currencies

International

Treasuries

Atai Beckley N.V - Common Shares (NQ:ATAI)

3.772 -0.028 (-0.73%)

Streaming Delayed Price Updated: 3:03 PM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atai Beckley N.V - Common Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations ↗

October 12, 2021

Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets.

Via Talk Markets

U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals

October 12, 2021

Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing...

Via FinancialNewsMedia

What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders ↗

October 11, 2021

Atai Life Sciences (NASDAQ:ATAI), a biotech company in the...

Via Benzinga

Where ATAI Life Sciences Stands With Analysts ↗

August 21, 2021

ATAI Life Sciences (NASDAQ:ATAI) has observed the followi...

Via Benzinga

What 9 Analyst Ratings Have To Say About ATAI Life Sciences ↗

August 17, 2021

ATAI Life Sciences (NASDAQ:ATAI) has observed the following analyst rating...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

Atai Life Launches Depression-Focused Firm ↗

October 11, 2021

Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. ...

Via Benzinga

Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery ↗

October 11, 2021

Photo by CDC on Unsplash Pasithea Therapeutics (NASDAQ: KTTA), a Florida-based biotechnology company, has teamed with life sciences company Evotec SE (OTCMKTS: EVTCY) as its...

Via Benzinga

Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028

October 11, 2021

Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,...

Via FinancialNewsMedia

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs

September 30, 2021

Via Investor Brand Network

Topics Cannabis

Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered

September 28, 2021

Via FinancialNewsMedia

Topics Law Enforcement

Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study ↗

September 27, 2021

The Week In Psychedelics:

Via Benzinga

Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases

September 27, 2021

Via Investor Brand Network

Topics Cannabis

Can Ibogaine Treat Opioid Addiction? Nasdaq-Listed Atai Is Launching A Trial To Find Out ↗

September 21, 2021

DemeRx IB, Inc., a company developing psychedelic ibogaine for the treatment of opioid use disorder, has begun a phase 1/2...

Via Benzinga

Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial ↗

September 20, 2021

AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares

Via Benzinga

$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins

September 15, 2021

Via FinancialNewsMedia

Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine ↗

September 14, 2021

Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsid...

Via Benzinga

Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics ↗

September 13, 2021

Last Week In Psychedelics:

Via Benzinga

Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗

September 09, 2021

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...

Via Benzinga

Psychedelic Drug Industry Report Card For 2021 ↗

September 01, 2021

In assessing the psychedelic drug industry, a primary focus for investors is drug development.

Via Talk Markets

What 10 Analyst Ratings Have To Say About ATAI Life Sciences ↗

September 01, 2021

Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021 ↗

September 01, 2021

Upgrades For Chatham Lodging Trust (NYSE:

Via Benzinga

21 Stocks Moving in Wednesday's Pre-Market Session ↗

September 01, 2021

Gainers GBS Inc. (NASDAQ: GBS) rose 72.3% to $5.58 in pre-market trading. The company markets saliva test for diabetes management and previously announced collaboration on covid-...

Via Benzinga

Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M ↗

August 16, 2021

Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ:

Via Benzinga

Peter Thiel Backed Atai Life Launches New Mental Health Disorders-Focused Company ↗

August 12, 2021

Peter Thiel-backed Atai Life Sciences (NASDAQ: ATAI) has launched a new portfolio company, Revixia Life Sciences. Revixia Life's primary mission is to...

Via Benzinga

Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary ↗

August 12, 2021

Atai Life Sciences (NASDAQ:ATAI) has announced the launch ...

Via Benzinga

Earnings Scheduled For August 16, 2021 ↗

August 16, 2021

Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to...

Via Benzinga

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗

August 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.